Results

1–10 of 32 results for AMD clinical trials

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Geographic Access Disparities of Clinical Trials in Neovascular Age-Related Macular Degeneration in the United States
Rebecca Soares, MD
Annual Meeting Talks
2021
Effect of Adjuvant Topical Dorzolamide-Timolol Versus Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
Jason Hsu, MD
On Demand Cases, Courses, and Papers
2020
Assessment of Progression of Geographic Atrophy in the FILLY Study
David R Lally, MD
On Demand Cases, Courses, and Papers
2020
Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization
Jeffrey L. Olson, MD
Annual Meeting Talks
2019
Episode 28: Brolucizumab for wet AMD (HAWK and HARRIER) - Dr. Pravin Dugel
Keyvan Koushan, MD, FRCSC
Member Podcasts
Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients With nAMD Following a Modified Manufacturing Process
Raj K. Maturi, MD
Annual Meeting Talks
2019
The Average Patient Does Not Enter Your Office: What Can We Learn About Treating nAMD From Individual Patient Responses
David S. Boyer, MD
Annual Meeting Talks
2019
Port Delivery System With Ranibizumab: Key Outcomes From the Ladder Phase 2 Trial That Supported Archway Phase 3 Study Design
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2019
First Results From a Phase 1B Multiple-Dose Study of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate (ABC) With Extended Durability
Pravin U. Dugel, MD
Annual Meeting Talks
2019